Syneos Health (SYNH) 3 Nov 212021 Q3 Earnings call transcript

Good morning and welcome to the Syneos Health Third Quarter 2021 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will be given at that time. I would now like to hand the conference over to Ronnie Speight, Senior Vice President of Investor Relations. Please go ahead, sir.

everyone. morning, Good Chief the Executive on Michelle are Macdonald, Colvin, Alistair our our Michael With Development Chief Jason call Meggs, Chief Officer. our Paul Solutions; Officer; of Officer; Officer; our our and President Brooks, me Commercial today Business Chief Keefe, Financial

those result discussed and to in about anticipated disclaim factors. XX, website to Reform com. at harbor obligation our the XXXX corresponding Remarks a may and and them. are to Securities indicated of future of Private These other is growth, for forward-looking factors remarks Factors prospects filings. that slide update December Risk from release, Form results addition year by as prepared regarding under results statements provisions for available various pandemic, XX-K make expectations, and Litigation expectations investor.syneoshealth the financial SEC plans, these forward-looking Act In constitute important the presentation a we safe of section purposes any we Actual the press the our our on materially XXXX our the our of differ COVID-XX statements ended

certain of with During core consider not accordance replacement will measures we a to discuss the considered non-GAAP in supplement measures effects These for prepared GAAP. financial and operations. a this be exclude outside events call, which we transactions our measures and non-GAAP to of should be

to our Alistair? please to I financial like non-GAAP Alistair to would of reconciliation the over of directly the GAAP a with presentation. call Macdonald. turn refer For most comparable the appendix measures measures, now

momentum. us demonstrating product again financial to another morning, exceeded all midpoint customer to the everyone our quarter and market and of of the We differentiated joining today. am quarter. I delighted results, across Good report strategy continued our for Thanks, guidance enthusiastic metrics response our strong the development thank you Ronnie. for

midpoint and in awards fueled the year-over-year our RFPs, in anticipate both during healthy in the December growth work and Syneos backlog environment this product the segments ahead life clinical we event Our above quarter; robust strong approvals strong those very of demand based business across new and we where their offerings, remains rates with both now models our across growth growth our drug the relationship quarter integrated for cycle, in pipelines approach. terms around continued revenue we XXXX outlined XXXX. us and discussions, during investor The One innovative of demand commercial

highlights three for Now key from quarter. the

and book-to-bill year-over-year. clinical First, for of for This overall X.XXx ratios XX.X% ratios book-to-bill quarter for commercial. resulting X.XXx and third performance robust Clinical Commercial net grew Solutions, X.XXx awards drove of by in Solutions X.XXx TTM for

continued of by approach integrated we and growth to our demonstrated strength enthusiastic XX.X% of Second, accelerating are as about business success solutions growth Commercial our Solutions the Deployment backlog and the XX.X%. Solutions revenue of

pleased our further recently service network we Both have RxDataScience, customers. closed of and expand assembly the Third, acquisitions innovation and to to capabilities. science offerings to patient are engagement companies dynamic bring technology-enabled data and our our StudyKIK enhancing

results. our on details further into moving Now,

revenue quarter We revenue Solutions recovery XXXX. strong see XX.X% company continue total our XX.X% to grew at impacts and the compared to of XXXX. Clinical third year-over-year growth to the from quarter the COVID-XX third of compared remained of

particularly by efficiency. scale in in ramp-up Our real-world in was larger full accompanied late-phase and including growth rapid and the oncology organic our driven continuing gain portfolio, our as businesses. growth This full-service they was by our relationships, pharma

Clinical and well into revenue particularly of beyond. quarter that in strong Our Solutions segment. and growth new robust pipeline a up positioned of by remains strong awards, also closed the another these opportunities, Driven is SMID backlog year-over-year sales, XXXX record team clinical ending XX.X% for record

growth further are we acquisitions, will drive and our Clinical across Before I recent organization. our discuss an Solutions sharing broader that update

As track are connections. into marketplace. XX-plus organization. executive partnership deep relationships our customers commercialization, Clinical development go-to-market be and mindset powerful, setting current product transformation. will aligns rotating Brooks, take Paul year Syneos to leadership we across solutions drive and to is way And driving record lead We Chief Paul's the our Health. focus product communities. Michael on constantly to customer-focused role accelerate clinical and across former Colvin has organization will trial Michael's with the strategy sites, focus are we're Business we Chief business increasing Shifting our and landscape decentralized on a trial placing now approach deep this high-value our lead clinical the patients, acquisitions; his will Solutions patient deploying our and approach enhancing advantage development Michael we a model, we to cycle as Development ecosystem as and life our customer transition continue Officer. Officer, will for the to and to engage recruitment. capabilities to believe our recent competitive physicians evolves,

continue our solutions and We additional expand Assembly network to customers. to innovative our as to data bring providers service, Dynamic technology

experiences start-up about enrollment advanced acquisition well expands network retention telemedicine the to their ability goal as with Through enhance sites platform, and patient for capabilities trial and patient and very reaching patients improve technology global diverse as engagement, capabilities burden enthusiastic access. engagement StudyKIK. eConsent, the are of our and Innovative improved patient clinical reducing include the and StudyKIK communities of populations We the participation. patient patient of to patient both accelerate of accessibility to added advanced by helping site more

PatientGO Clinical site reimbursement and SourceGO, focus platforms support technology to support capabilities a a patient and unique In ecosystem. integrated is travel, addition, connect opportunity and creating support. remain patient platforms, and patient our PatientGO see an home key the support caregiver services application service our concierge of We and compelling health with patient StudyKIK service facilitating concierge a Solutions organization. for site

patient capture SourceGO with data is in Syneos technology-enabled Health home securely real decentralized delivery. positions enables a as a our trial further clinical recently visits. health our services capabilities health high-quality home to released time leader in mobile application during Combining these that nurses

solve biopharma advanced problems through to analytics, RxDataScience specialist clinical lab-to-life customers We management the acquired phase solutions spectrum, that development our our model, product aligned organization advanced analytic AI. offering challenging also and across recently late real-world well is and increased for us and omnichannel Kinetic, from Combined RxDataScience, via real-world generation helps existing to RxDataScience protocol modern entire in allow our a capabilities, data evidence data science commercial. analytics. These help analytics of will like cutting-edge trial accelerate including clinical diversity, solutions analytical customers. clinical engagement trial drive delivery areas trials, capability, and clinical performance to decentralized insights, with solutions

distance harness solutions companies structure address capabilities, rapidly most to and drive their challenges, the goal to difficult data offers we excited prototypes the to of excellent of biopharma data massive increasingly bringing AI shortening make further in develop services value. lab that about significant to I'm our continue customers and life. and our As organize the latest sets strides innovation to RxDataScience from technology-enabled helping to

team our offset continued the our to saw to XX.X% medication core partially headwind accelerating XXXX. This adherence now Solutions; growth level, to the our XXXX outpaced of growth third year-over-year we compared revenue business across divestiture commercial Turning the this Commercial of of broad from Growth another specialties based commercial by business. be growth quarter in highest Consulting a growth and Solutions we backlog to number high-performing had of our communications X-year our Deployment businesses the driving the new resources also the business. medical public ending quarter of rate of had experienced relations high. in communication services. and starts, and deployed impressive within

basis a are gross commercial over awards full-service year-to-date on up addition, compared XX% XXXX. In to

drive We consistent innovation, expect part remains pace to drug adoption more success and biotech further of continues growth model visibility environment. our as and customer the new the to approvals The this for increase. commercial commercial services by funding of revenue market driven in the integrated strong, enhance

in We expect quarter teens. performance Solutions with high again growth the in to fourth the Commercial continue

fuel referrals through to capabilities. capabilities Our with patient to commercial accelerate clinical development Kinetic targeting into trials optimize in as product advanced engagement spectrum and such the commercial dynamic expertise and designed across innovation is Kinetic. HCP digital continues

average, Our these innovative XX% commercial studies capabilities, suite producing, early activities. across and unique Syneos believe in improvement We on a other of our with along Kinetic indicate this that solutions, clinical case driving is Syneos awards. particularly product to and continues differentiate Health, midsized to factors also continue end-to-end to differentiate development customers. business key small methodology, our in Syneos are with Health our One, new

launch success these only the During commercial the first managed we assets Syneos One among began unique XX and launches. team, significant the the demonstrating offering third marks This milestone for of a the is of this first by currently quarter, team. our the

We have also XXXX, planning during expected approval. two the to commercial regulatory first One launches additional final activities of for half subject Syneos initiated

the half for product will also way launch the same we that quarter, these beyond our an anticipate of relationships reach European and growth We launch backlog another XXXX. expanded one U.S. second pipeline. the One Syneos can commercial start largest drive include our existing and awards activities revenue also Canadian to diversify This One geographic Syneos the asset. Expanding contributing launches in yet to asset of and the demonstrates of

areas, the to over expanding the indications product around with the therapeutic regions globe. commercial revenue expect an launches portfolio coming Syneos and multiple One and We to contribute increasingly years in diverse awards of group

outlines a for their Lastly, efforts issues while I to comments inclusive provide the and I important our to pledge Jason our entire equitable for and annual to impact. environmental community to third our sites worldwide. of sustainability fabric reduce positive This customers, these to service commitments company's creating which patients passion commitment It highlight diverse, represent performance now report. that they Jason? publication wanted a Syneos showcases work additional workplace continued financial thank XXXX guidance. to the provide will am Health the of commitment impact. tirelessly and also ESG to want these our our our social proud on and excellent employees recent while report marks the making and I our culture. our

Thank everyone. you, morning, good Alistair and

was constant of revenue for the up total quarter XX% was the pandemic. COVID-XX and quarter third in by XX.X% billion, currency which of $X.XX XXXX to compared XXXX the third impacted Our

from constant Solutions was the increases the real-world of including full-service XX.X% increased This growth basis XXXX. point third point billion, includes third portfolio, total These expenses, business. reimbursable strength our for the XXX and revenue quarter quarter and in compared in Our a to tailwind driven and XXX in a XX.X% larger contribution our expenses. acquisitions $X.XX reimbursable from were late-phase ramp by or Clinical up our in growth relationships basis currency pharma higher

was and in the third compared year-over-year, quarter of increased were growth includes the management core adjusted Commercial driven basis impacts expiration in broad expansion diluted favorable currency Our revenue lower double-digit $XXX.X Solutions XXX a commercial in commercial or of across quarter the EBITDA our points The programs adjusted costs program. ForwardBound in million, cost in with $X.XX XX.X% particular strength by XX.X% quarter expense. the businesses, primarily compared was of our from was third consulting Adjusted up XXXX. to quarter revenue EBITDA by Adjusted mix. and third includes Growth third the to expenses. by less revenue XXXX $XXX.X constant EBITDA quarter also by third business. for interest basis divestiture XX.X% basis impact partially driven XXX margin an offset of increased the XXXX the of of the result from the savings EBITDA EPS our million, to These in of headwind primarily of This margin increased a a and a revenue XX.X% the increase benefits the in and point temporary of adjusted initiatives representing from decrease XXX growth instituted medication of tailwind reimbursable XX%, point adherence XXXX. decrease for

million Our collections. for operations and generated part cash quarter, due in billing third in the flow to of timing the $XX.X

flow operations the Our net by cash has driven as impacts from solid, of pandemic year-to-date million, subside. $XXX.X XXXX income the primarily reaching been our

seen collections We flow the XX.X a and normalized unbilled in fourth in for DSO driving activity and days, increased already level the accounts and expect revenue. October. improved have receivable more resumed, to returning operating quarter as quarter revenue was cash billing strong growth

of leverage and cash $X.X $XXX.X net the of third quarter. million debt with were outstanding billion, ended X.Xx. expenditures quarter resulting in $X.XX million capital of Our We total unrestricted for the

we of acquisition highlighted, Alistair quarter. As closed StudyKIK during our the

net be Given cash second of expectations expect higher leverage through end slightly our of our facility, to compared the year. net prior and the that leverage on draw related We Xx $XX ratio to a currently the million our slightly than below quarter. increased utilization our remain revolving this credit

our expanded we our to overall proceeds million October, in $XX addition, will and In we by revolver of securitization serve cost our facility outstanding reduce used AR debt to which balance. the reduce

the for third the quarter tax our year full with for consistent Our was rate non-GAAP XX%, XXXX. effective expectations

Turning now on factors to change. of outside and business, COVID-XX recognizing guidance impact are view related to company's the our control estimated of updated our XXXX contemplates our COVID-XX that current guidance; to of this subject the

XXXX billion, billion approximately of million. adjusted We're We points. to are continues points XXX XX.X%. basis growth EBITDA narrowing year range XX.X% to This adjusted full $XXX our representing EBITDA basis to includes expected XXXX to from This divestiture XXX points of to from $X.X narrowing contribution of headwind XXX our estimated XXXX the a million total also to growth XX reflect of to XX.X%, up expected and midpoint. basis range an $XXX revenue margin of of XX.X% to from $X.XX our acquisitions an

reflect to depreciation. $X.XX expected adjusted $X.XX, increasing are XX.X% we Lastly, range our expense or of expected interest to year-over-year growth of and XX.X% EPS to a to lower a diluted

approximately of shares. a XXXX of estimated of XXX.X million share expect now we from to an Further, million, expense outlay range diluted during and cash for income $XX $XX interest tax incorporates million. XX% guidance non-GAAP million $XX net our rate taxes effective count Our to

As Alistair we backlog expect segments, communicated awards, the exceed growth at of the pipelines strong on X% we XXXX XX% to highlighted, Day based in our to and our XXXX. Investor trailing range XX-month in our midpoint both

expect considering ongoing we from Importantly, clinical particularly in strength notable and commercial. contributions commercial, both the

This higher the our compared adjusted commercial, answer XX points be reimbursable any expenses EBITDA expect increased prepared the of questions. XXXX. completes XXXX Given of to and to XX contribution in range to remarks our somewhat expand our we from to of year mix we Operator? margin would for a basis full happy expectation and now

Patrick first [Operator from comes Instructions] question Citi. Our Donnelly with

Your open. is line

like about your deeper to pretty to right confident again, of above guys your a up, into Great, starting sounds confidence thanks the visibility way you setup guys. on level? -- talk It Alistair, little midpoint guide the commentary just it maybe going like are a year. about think Can the the long-term little maybe 'XX sounds love the next some there, set there. would that is but on you

start Okay. Yes, for and I'll the Jason add. will Thanks question.

deployment think you yes, that got good mentioned that. long winning view Also style products we're both pipe for also with year view approved that through the whole the seeing new pipe we're more right We side coming Obviously, the now, the that backlog of and from I lot kind from with a that's the increased backlog, backlog where the we're the trend through gives commercial, So visibility visibility of that with backlog deployment coming the we the and a commercial lot products of of and full-service of really, that getting on the amount longer you and through oncology sit work those work. winning up clinical. also sets so new around commercial a getting of fact that approved. through a

going the SMID folks commercial have owner been and to very for to model model to in And seat. products market. those are approved obviously, the think products through I Syneos than the with integrated a XXXX, the One have we still market XX% So solution the that of in more take good is that those the

So I that. all think see we

We also customers, see in FSP. we're of that's in of strong pipelines RFPs, having terms way work very coming terms discussions our with

I in than And this across have it's accelerate. a think right at it see seeing we the a would We're setup point. So really a business. nice better normally look XXXX picture just we at healthier

a XXXX. bringing you we're can the little let add? thoughts, confidence Any touch that come in little So to a bit for through happy guide Jason,

that's No, good summary. a

And but mean sounds RFP hear little bit great. That's And it's quick the of about side COVID out talk a you backlog well, just helpful. revs above on there. then activation be there. a would you can of site encouraging touched flows levels. kind the just to the the the on I maybe really and That's going update composition like then pre-pandemic

Yes.

was of that board, of the flow is is scale large scale really SMID. that on pharma and So to across pharma, strategies important. get we're drive imperatives I strong to that pharma. into to large the into think working more That merger get been right seeing, one the the large We've RFP penetration both where the

So issue the And a There's that as a and we certainly, see in SMID market SMID an it's I that compelling lot hand don't see certainly funding got market. forward. that most that. we're of the fluctuations either. the as offering of always an from the cash seeing have the biotech healthy pipe We, and the but see, think, we part not issue that customer has in they is index on go we

I continues like in are still little Site activity that, is to good. is and still patients bit they're things therapeutic issues recover. some cautious. areas and think setup think immunosuppressed that strong, So a I with There

So enrollment, little areas but bit I think, coming it's still in therapeutic back. some of the lags a

forward, as that's to we've So got that pull through. I And encouraging. those very rolls patients think

some start-up, lot we've of actually processes bodes patient in for study to and which mean StudyKIK hit start-up A time technology we I that the projects, in goal them. our think to not accelerate those the lines is I do. that. made for engagement but well to improvements addition is around just what more

our that to ahead site faster and processes continue see business starting accelerate investments for and in technologies the projects think to and to to we're I more more that the we that and And projects. patients way changes and get look we of start-up, So in get delivering. conduct into we're

Patrick, there. COVID win to work continuing we're then And side, the Yes. on

then revenue of to ramping in I that quarter burning clinical, in down changes in two. projects vaccine under there The the think, three. about some I bit just higher to three and quarter contribution It's down, up had come slightly across business. two, in think in quarter And was won that quarter trial clinical. than terms to X%, continue COVID has of did with the in ramp a XXX for that we're backlog almost we

So that. any good we're mix so with concentration; heavy there, happy super not

Thanks, helpful. Very guys.

you. Thank

comes question with next Our Tycho from JPMorgan. Peterson

decentralized how if couple of I'm decentralized you about you approach? we deals, goes over wondering what of fit And as more your in the Alistair, and recent could And thanks. next Hey Illingworth you little a talk kind think strategy, broader StudyKIK, kind your RxDataScience. the backlog bit years? about with the of of think percentage did

Yes. Good Tycho. question,

we been the it's earnings the you at I but decentralized, you before you up looking talked have the patient, one a last so always drive go whether So call, down, this, end we about based whether think, business right? patient. direct might how around whichever in patient, trial, go channel So it's -- -- with traditional we're forward the to

So that take regardless we're we're technologies those at looking at capabilities us the looking to and channels. patient of

patients. have for StudyKIK we that that around around the the around executing putting addition can sites, and team. on the strategy ability with -- great big StudyKIK, around we elements to telemedicine, what Illingworth adds can the deliver only the but patient. have our work this We quickly The receptiveness been catalyst they not deliver identification, us Illingworth. help that on not through services networks to with a abilities We together, to the We've So of pivoting see identify StudyKIK patient capabilities that together are network their engage we're this get engagement, They enables tremendous. for of years. that strategy they putting patient a decentralization all from several of It together, in up engage terms key then with we're site some that also a their what the as patient customers to worked elements sites and fit addition to their has do. we're executing great

services event was and great we just of site but would all look rare in what trials, telling a an the were them, for trial have setup. decentralized home their able they were patient, -- to them us patient It the was attached Illingworth in to services weren't the then at that them somewhere. it's forefront me out think right the couple properly. Russia they that's that from at a engage about that. A a ago decentralized weeks about recruited should away like. and to delivered It's not actually puts XXX I I that's delivering of they and deliver brilliant. the if miles lived that patient disease and trial been And enroll lost is talking

taking the You're that enable trial you've and like -- taken technology, them. deliver to burden down down nurse. barriers and with Things on makes PatientGO the us patient SourceGO, all the takes to the that visiting

these strategy we that all trials. because actually can So, accelerate deliver starts really to

we Can is consolidation driven That's kind couple helpful. noted from of wins, some are how of on standpoint? follow-up the quarter, with competitor go competitive wins, last of talk given If a FSP. there And being you the to momentum a then, multiyear just in by continuing, what this the background seeing back much big on you you And a deals. Synteract?

of the another a couple I think, Synteract. have one. much added has had into did we now. FSPs work by been that absorbed small Early another the been of We QX, in add team big Yes. They relationship, QX. FSP Not driven FSP

in think team. the I safety was it

FSP for new good. FSPs. yes, the is I think, demand, not just It's So the

it's seeing think flow lot ones the expansion a I well. We're of of there. the as current

more rapidly customer internal, to difficult to that as are from loses part well relationship deploy backfill resources If plays from we or find, a we a we're loses that more through because as As can. I a somebody FSP. think and as more another resource in FSP quickly can able

key think I that of one the which CROs have one FSP the you that I the we've well, with being think we yes, of So right largest scale larger the stay to that chance pharmas. is I a is elements and -- -- -- can won't says, resource we these the customer of market random deliver with locations what I got is have comes FSP well, think But here resourcing models better particularly now I needs with be need a large the here, CRA much networks. it but in able quickly and when to a pool of a from fill being that, to along say is

have if of we with find Partners help we pool to. we a big that us to on work in contractors a a agency need the is people Taylor We regular that But as needles have recruitment internally, teams, have Strategy able haystacks basis, well. we

So FSP compelling we're in I the think space. very

I we'll think of the very, a ago we continue has and growth XXX very FSP that model well drive couple good worked to launched years in that sector.

And consolidation competitive all kind front, just background, change are any the ground? on the given seeing the of in you the on

That's asked I is Michael. Paul probably guys run a He's run overall over today. Michael's and seeing mean -- question and I've to to strategies. clinical. moving Paul moving go-to-market are the you here over well

So any guys? those two, thoughts on

that that to impacts are the having we're think in continuing with are marketplace. other some But overall, the partners out see all some consolidation, I disruptions. competitors of the still

service the in but strong. remain ourselves just differentiate continuing DCT especially offerings, think our with we're competitors to I

some offerings I differentiated with think we're competing just now. against right service them

our Yes, I engaged customers that, the top are as receiving protecting leaders, very sure am focused with on clients our which, very agree. and how current in I that questions Many environment. stable our making culture with of life around employee priority culture, our our our how cycle, executive course, employees we is around and focused of we're the

guys. Thanks,

comes Our David next from Jefferies. Windley question with

Your line is open.

pharma the remarks portfolio. fairly been perhaps guess ongoing the your if this better prepared an I to running Alistair, know that Jason's relationships, or has to well were early morning. maybe you wanted large seeing new I try expansion winning kind of as the of emphasized good three large questions. point years Hi, in in if emphasis. ramp pharma as I wins or you're for some taking are understand in even some of call-out-type relationships two Thanks

now a a a so but new I bit won entry of operationally. It's remember we have day back the couple little in into of tailwind get points pharma, years going you well. relationship, to get that you both. these done in back to think -- Yes. we're to large prove I ago, a still And that if pharma when the you're we've starting was and It's think say large you -- from it to especially when I yourself bit new, as

get saw awards in us relationships QX and oncology They've start come trials those seen perform, from couple back big they've So through running. we that nice us of we some up established then. a seen

months of Of that COVID. of has teeth relationship been two the year course, XX through

So I think well very we ourselves and well conducted through delivered very COVID.

of getting So bigger if got through pulling now and only hunting we're business, wins, bigger entrusted we with license be the you and kind programs. repeat not the like, and those early

years relationships and that's established we to work those of the additional accounts, in So of Client additional those executives from We that some able a what's new our been team happening starting is competitors brought ago, who in Global XX. deployed of in more of and top some come in in have wins. to more through. And are establish -- us couple Solutions penetrating the

here point yourself couple getting Now and etcetera, we're us couple here preferred on and a and We're go. up picking we hunting and rescues got because of providership new a prove preferred a haven't you provider trials there, And anything of we're announced where license that that then we've list they've a to you given list. then move getting to there. the

ones we those of how forward So going pleased that with some relationships. we're we're it's with want and newer how yes, the in moving that,

It's but a Excellent. question over flipping commercial. of related to kind

opportunities year from of in that of launch. a a where the fair that percolating time your well remarks prepared in mentioned that were you full-service last and commercial as your Day on amount You including was Investor your did some spend business, at time focused

to of maybe and about that's supposed the was anticipated those right out I'd curious your commercial of business. in ways about for it's first that going you playing comments the think the I just quarter at end on how closed now. the be launch if beneficial the

Yes. ear from Well, we've got Michelle grinning Dave. to ear,

Christian fits So about of to with we together there's commercial SMID think with a that mean have that we're strategies but are market in as it that that as inVentiv we're I sector. full Syneos I'll of assets of customers. Syneos that Michelle's fruition going got built backlog pushing really bit business a those booked I a that One won model, off. through, products through that the with And she's starting to year, and come now seeing we've skepticism to XX% how work, been a XX you targeted conversations as and to to in see We into pretty But kick We've the team else SMID that put we've of do. lot but lots tell always -- hefty of everything This we're I his out One. jumping of together on. merger. together pipeline we of think come into run the put came starting haven't see an work domain. idea starting we we're now following our

yes, hand are about Michelle the a tell to you of it. So more and over in bit we going launch that you and I'm teeth to she'll

I asking excited so it. question, the David, me I'm on answer So you counting to was

was team did the City, shared the I to actually layer and having over division. Alistair to with Syneos go the do. having there, going team Utah with to commercial summer. you be we're lot And that first So was we're And that One with into of a success we in able what success just launch. to Park is I our the starting asset

start from we coming One is announced of team approval that deploying and January our believe in which really press we'll Syneos we've release, XXXX. a major that know, launch in early you in publicly second QX joint As that

the to have There's to sure we having that. success currently. do we're we that we're have very commercial So continue very, three about in that excited to make things

The make first bring we those and manage One sure fruition. flawlessly the to assets is Syneos

great a doing we're think that. I job with

thing being continue integration of the those double second is The win impressive -- the growing I cross-selling Solutions. area is digits there. And the third up three very class all QX. are seen it's businesses to thing you've to awards that in consulting, And and through on best commercial businesses, in individual in and communications Deployment in XX% think we're and

all on firing are right for all counting things on long-term now. cylinders the all So commercial success we're

they're And the teams so very to just it's see having. success for exciting our

with Great. that. that. leave will Congrats on I

Our with next John comes Kreger from question William Blair. C.

Hey, guys.

Michelle. Another and for the commercial business one

on Now three that of just or can with business this And up, business now picking expand to makeup down? be things mixing right a sort up the should mixing things? One, as kind sort those across the about what's commercially of bit integrated seem you particularly to two the of be thinking buckets? starting really of contracts we ramp,

John. Yes. off. kick Good I'll question, it

think we're good -- Across communications strong clinical growth all the across across consulting, we'll think again. start sorry, that Deployment seeing I I not three. in Solutions, and clinical,

commercialized from as and Now their the work their integration, commercial Syneos accelerator but individual from that's into work consulting, the is go-to-market to we're the seeing etcetera catalyst, think that end of the One the picking also commercial work. that the goes the integration launch, well delivery. from -- up launches the then getting them communications, planning, real as And is the of kind I the

going new customers bringing years a it's been think talent well. couple both. that businesses over All last I bit with earlier leadership So three of the help the drive new engagement to cycle. life in in Michelle has of

into package. combination I integrating then business but So a line success kind it's a of think them of individual

As it's last as XX% was it and well. Michelle said, pretty up heavily year-over-year year up

of a seeing, that's So that taken Michelle? market towards definitely the delivery trend integration. I think, us

Yes.

successful I really very that. is And been types only in I right, add our hard doing customers and customers. across diversify thing will the to being think across of we've working backlog, So we're

relationships with seeing the integration that great also XX you're us pharma. SMID top commercial do One seeing and really Syneos flow but you're work with great have opportunities really and We customers through

really that diversified. our think is I backlog important it's So

customer any relationship or team seeing rest. the any one one dwarf not communications or You're

of backlog visibility been into really I about because Solutions for we think I saw that's better the So for And up And the teams to not space, They're backlog before. of and backlog be Solutions affairs, that. hybridized. good reimbursement. from folks, a really different the in right? MSL XX%. kind field in really matters just much over that. have a business are important the that conversation Deployment think feel is Deployment complexion sales strongest the you metric moving we it the is is this that anymore. had moving very med that probably still this business seeing say The So numbers We We're script. growth perspective. have group in But into of visibility much reps that We've we the commercial backlog nice

part CSO And that's moving I that that a this CSO, think a a see big to of for been not the we're to and so the saying success fact Solutions isn't while, going forward. that Deployment continue a we've it's

gives that more hopefully, you So little color. a

one does. It And follow-up. quick just

you're the drive the up the guys you coming currently all seeing, that given what thinking about ability two one to years? success or are So in margins

I'll to think Jason. that I hand So over

Yes.

across that those And time through move those smaller but largest launches to see grows. team full-service segment, during had look it's in of are time. the services, traditional and anticipate teams in the Solutions continue away we'll still that side is commercial margin in that will continue from the as at stand-alone come we as the Syneos see sequentially you'll When which margin to be moving higher-margin it's opportunities get So your good One business commercial see component we Deployment as well will three wins the quarter a that that well. over numbers you there Michelle's tend reps that multiservice, over assets as higher into the things in to then we as of and

over headwind traditional where around time, come whereby time You could in be a as it to back growth, certain up have team but can then you little stand might it's all going well. points good of margin bit a a

they're also continue So, and via ForwardBound, our or more on and basis opportunity efficient, a there grow to our it's we around contributor a operating resources. the program using automation key lower-cost see we can global to optimizing model to margins everything whether getting

leverage and So get we opportunity an good business. see SG&A that finally they then out of also excellent

you. Thank great. Sounds

with Our Hooker KeyBanc Donald Capital comes question Markets. next from

open. is line Your

I out or guess, a XX% morning. I intrigued good that metric threw something. by, was intriguing, was Great, Alistair, you had that mentioned you

Is earlier your elaborate portfolio? industry And of is there? a to commercial. all small I think that One that questions seeing sort biopharma a of way you metric? the are reference you're the Or taking Syneos XX%, own sponsors what maybe to of SMID on can mentioned one an you product the

Yes.

Thanks. think yes, good I Don. -- a it's question,

I is the think portfolio Syneos or One four SMID. is assets the -- all actually other than of three

actually higher So us, it's percentage than XX%. for a

So would over XX. I four mean that what be

Don. the reference is math actual You out. are the I work that XX% marketplace, the think you But guys guys,

products So are coming the year products if those of at over you XX. top through, XX% look launched outside the this

So we puck together and kind put moving where building platform, execution the medicines. strategy, Syneos market, think sell think we, built it And And are five that's for resisting delivering years through us SMID to targeting somebody product planning to. full completely would are cycle the or we whether something taken to to the affairs, be five was is them. said where time, us. those the was personalized a about on One hanging life customers at I four what the And through to we're They have specialty them temptation we who the going the that is all think and else then medicines, think longer, is in assets the years, their of puck way commercial med the delivery ago. -- it we're approaching were that I years clinical, the I team of the market going the they through to

that's where through. fact the put to learn sense deliver So we've organization starting the had I'm all pleased we to the that time to how in and and very build it that come with and

in product that it's -- way pulled the out all we've think the validation stage through model. of a is first model Utah that good I we've on that Michelle launching the

So good products of concept had. of that are it's have proof line well. And moving through the a validation we as we that that of now a

think well. of the we capital with it the determined market markets one to would So their next that yes, very products own be, go where the put I and people develop then to positions the and predicted and us kind on access

maybe Interesting. other one more mundane then, question. And financial

this to year. cash taxes, the of looked lower think actually be even terms going it In like I it's

some going to So NOLs. you through those point? get are guys NOLs tax going a cash are this at burning expire rate and When normalized you're more to

Yes Don, it's Jason.

when to we've been probably maximize and and terms at looking we of into out going component that working of push So can final how use the NOLs. think and it's we'll optimize in on XXXX the

will just taxes through don't It's until the cash XXXX. 'XX, NOLs up. we'll into all forward go move we think I burn as However,

Okay, good Have thank much. you day. so a

Our Elizabeth next Evercore. question from Anderson with comes

what of bit the some if talked also hearing hiring we're inflation little news in wondering the 'XX competitive the changes there sort for sort in specifically I broader at about much know of the specifically on and percentage and a your and what was you're seeing I so of given wages comment peers. vis-à-vis thanks the all the could then guys, outlook. environment wages trends just in of about about Hi you just question. environment about the margin you

unpack think starts I We'll there. And strong, little it Okay. that is a demand all bit. Yes. right? The environment

to that's little passing a but still So through. bubble It's COVID there ease bit. the you have starting it's

have that environment, the of seen an demand hiring little as environment bit a easing well. I in think because we the in

that for. engaged attractive people are organization we're are that people a model. to hear got we got about that by a that life work We've come So culture. It's we a lot. an and cycle product I think and by good different and a engaged want lot. and that hear We've People delivery

hotspots, that in space. some areas. much grass into which oncology, is etcetera. is few been And That I the have greener. always that of a it in like positions, count people some think There's unusual we are is Asia, we I disruption particularly, and pressures some at organization driven people think, the costs, that not -- communications who pretty back come there's the left market on instantly areas great. the that's had XXX inflationary But then the shows remember, seeing also last something I of

the think I if the about count, I incremental remember to X,XXX we've managed year. add, heads it's last through

comes cost yes, with that to able up through. to we But deliver. be So that and keeping demand we're need the

reviews. Now our in. obviously, the and through the to big get And of the in the ability contracts. the to We we're of that have part pass we back inflation customers bringing majority go of inflationary personnel cost probably a is

and of to out. the and network that we're by that handle of off those ForwardBound people bit move with we jurisdictions, we're as to efforts Syneos to tasks a able able pressure defer the little that lower-cost operations take Now some them we price the have,

right? multitude to all I Jason? a just shifting other always do got and to service we're the costs costs we're lower-cost there's Any the shifting all going think strategies thing So do lower same thing, we've countries. thoughts, and levels of the us, the not businesses that it's where on CROs same other

forward, success would I just Yes. us. say, would been real as we I for Syneos a network look the has say operations

We things will automation G&A as getting be we continue about But within simplifying and selling going probably maximize organization able 'XX think things to beyond as more biggest that well opportunity just the be as efficient us things to both to certain even can. for scale. is to and and the and side side businesses we across the in single where right of of

very on we beyond. on move more more getting just will help We're and that. focused into us that as and we're focused 'XX and that So

and the into able it, in those that super is RxDataScience, of for long of them to terms being of the Got integration you sort process then helpful. with like some StudyKIK that's portfolio? plug etcetera, assets your And some the announced, acquisitions how of just current

for good years. with worked Yes. StudyKIK That's a question. And we've several

across So already. pretty particularly the processes of the our engagement, is and sell business side much the there

some that services connectivity of connected that be concierge bits cases we have, the can at attach that we together. PatientGO, also there use we we of have to other think around are I that looking are need SourceGO, several technology will where

those customers the So market connecting to actual bit of then time. those take, pushing a -- takes that the is into out will quick. But of those obviously, and quite little what rolling things

capabilities, they've look that cool and questions using mean very data Rx stuff. is large -- But have success. I in what done do different it have. that's their driven with like, it some out done, But things their I they almost individually of handle at using customers data I the this platform to that just right don't work that wow, some to the are on groups science Kinetic and used I They're and complex, was working the just RxDataScience for who massive without word probably extensions insanely is questions think team. products now. what where label two done, but have together. looking RxDataScience we I to just at traditional anyway, built That's the sets We'd really -- going running have data work the to the say able side, think our right people mean past, difficult put from to in -- we've identifying traditional being of is data and coming -- those in able science be science where people, could play RxDataScience on a further be data really and get trials.

a reputation model So our of new high just able because incredibly line. able value service adds has with do that an for to different a into arena, to step us, company that a to we're we're lot that

and that commercial. that in to on kind apply BD of get something we've and the door clinical and of working because Now can it's the the rest the are customers that Michelle, to guys And right who got the thing. Michael, are train team Paul, we across

it that us way will customers. So we're take deliver in optimize time very some to excited we it time. take about some to the will for that. it It But

That makes sense. Thank you.

question Our Sergott Barclays. Luke from comes next with

my taking Thank you question. Hey for guys,

So us allocation months. a story? bigger is an didn't starting buyback update quarter. X M&A priorities a in capital the part Just of out give next the if and to Can you the you on your XX do to the thinking over like become guys

Yes.

think We're hit. get looking before. are that we believe to I debt, out pay priorities So the down same the down, target to started as leverage the to where we continue

at we at in around StudyKIK, and to how at invest that we into us invest Illingworth, So looking differentiation. the all bring that we points And again, customers pattern we've have patient, how did continuing done then what we're buybacks been we When this tuck-ins look we doing, it's to that services when we've that's this we new that we entry continue the happy look about do bringing of to do. down. year. keep planned around M&A, Synteract, RxDataScience, new

thoughts? any Jason, So

Well, just yes, than finer tuck-ins been the the at three to mentioned into end year. look a below what point the on half Then it to but being always focused that's it, priority paydown as those is see on still already dilution. second debt our I first the prevent X.Xx year delevering. But than higher mean, bit to Xx. we put of be will M&A a I -- I through. we'll through a you move in share we mean, at something that's mind, next and repurchases coming of this done that and year, just We've continue to

work All outlook that's a where reimbursables seems right, the your higher that in and contribution I reimbursable? if of Can guys all, how give us to lastly, then you guys you up. winning, And fine. be mean, all at have that, that due to the you COVID then the with raised been recent it, 'XX sense vaccine picking on much of was quarter? And

Yes.

I up. let back So trial during quarter, vaccine did guess the well, we -- see our me that

out we've down, therapeutics. ramped normal it's reimbursable mix higher ramped sort than we and during We've Not starting And to puts trials that that to talking where trial year. is expenses of to and points three, of that down little reimbursable the landing about margin the XXXX. are some been expenses look you I between be still update normal accretion their into nothing and to and guidance, did But quarter a directs is too at that our large down. did there on the of the reimbursable that rate it XXXX quarter right? majority we're four start expenses multiples, to vaccine directs. it's prepared going get significant to that in as XX coming remarks, how the When relative a two pressure But able but burn and basis to So the quarter on margin. have in XX clinical come mentioned given the into that's hard come and to going increase of have one going

I'd call no Macdonald the like further for Alistair back are turn there And remarks. questions. over to closing to

investment our challenging and to continue market Thank sincere all our manage XXXX our Syneos in you our a circumstances good. thanks positioning continued Thank safe. look to interest for to strong day you. growth for and beyond. your in while do great confident Again, today be We profitability, remain particularly they the you. delivering and be team through Have to for and for in entire organization. customers. forward and Thanks your Please attendance thank and

This for participating. concludes you today's conference call. Thank

You disconnect. now may